CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
Se Hyun Kim, Kyu Hyun Park, Sang Joon Shin, Kang Young Lee, Tae Il Kim, Nam Kyu Kim, Sun Young Rha, Jae Kyung Roh, Joong Bae Ahn
Cancer Research and Treatment. 2016;48(1):208-215.   Published online 2015 April 24    DOI: https://doi.org/10.4143/crt.2014.314

Excel Download

P16(INK4A) Gene Hypermethylation and Kras Mutation are Independent Predictors of FolFiri and Cetuximab Chemotherapy in Patients with Metastatic Colorectal Cancer (MCRC)
Annals of Oncology. 2012;23:ix185   Crossref logo
Link1 Link2

<i>p16</i> Hypermethylation and <i>KRAS</i> Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
Cancer Research and Treatment. 2016;48(1):208-215   Crossref logo
Link1 Link2 Link3

Cetuximab plus FOLFIRI in first-line treatment of KRAS mutation-negative, EGFR-positive metastatic colorectal cancer
Community Oncology. 2012;9(10):304-306   Crossref logo
Link1 Link2

Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population
Medical Oncology. 2014;31(5):   Crossref logo
Link1 Link2 Link3

Retrospective Study as FirstLine Chemotherapy cetuximab plus FOLFIRI for unresectable KRAS wild type colorectal cancer
Annals of Oncology. 2016;27:vii99   Crossref logo
Link1 Link2 Link3

Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer
Chemotherapy. 2015;61(1):51-56   Crossref logo
Link1 Link2 Link3

Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306
Annals of Oncology. 2012;23(10):2771-2772   Crossref logo
Link1 Link2 Link3

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Yearbook of Surgery. 2012;2012:322-323   Crossref logo
Link1 Link2

A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
OncoTargets and Therapy. 2015;1061   Crossref logo
Link1

Retrospective Analysis of Patients Treated with Cetuximab plus FOLFIRI for Previous Irinotecan-combined Chemotherapy in Metastatic Colorectal Cancer
Journal of the Korean Society of Coloproctology. 2008;24(5):345   Crossref logo
Link1

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.